ASH 2022 | ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter’s transformation
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, shares some of her highlights from the ASH meeting, mentioning promising data on glofitamab in diffuse large B-cell lymphoma (DLBCL), and on pirtobrutinib and epcoritamab in Richter’s transformation. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
TG Therapeutics: Consultancy, Research Funding; Genentech: Consultancy, Other: DMC, Research Funding; Novartis: Research Funding; Abbvie: Consultancy; AstraZeneca: Consultancy; BMS: Consultancy; Adaptive Technologies: Consultancy; ADC Therapeutics: Consultancy; Beigene: Consultancy; Impact Bio: Consultancy; SeaGen: Speakers Bureau; Celgene: Other: DMC.
